Prx-I knockdown inhibited the proliferation of T24 cell

Proteomic analysis of bladder cancer indicates Prx-I as a key molecule in BI-TK/GCV treatment system. Jiang L, Xiao X, Ren J, Tang Y, Weng H, Yang Q, Wu M, Tang W - PLoS ONE (2014) Bottom Line: In order to understand the molecular mechanisms of Bifidobacterium infantis thymidine kinase/nucleoside analogue ganciclovir (BI-TK/GCV) treatment system which was proven to exhibit sustainable anti-tumor growth activity and induce apoptosis in bladder cancer, a proteomic approach of isobaric tags for relative and absolute quantification (iTRAQ), followed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) was used. 192 down-regulated and 210 up-regulated proteins were identified after treatment with BI-TK/GCV system in Sprague-Dawley (SD) rats.Western blot analysis and immunohistochemistry analysis confirmed that Peroxiredoxin-I (Prx-I) was significantly down-regulated in bladder cancer after treatment.Prx-I silencing by transfection of Prx-I shRNA significantly suppressed growth, promoted apoptosis and regulated the cell cycle in T24 cells and reduced the phospho-NF-κB p50 and p65 protein expression which revealed the links between Prx-I and NF-κB pathway implied by Ingenuity pathway analysis (IPA). View Article: PubMed Central - PubMed Affiliation: Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. ABSTRACT In order to understand the molecular mechanisms of Bifidobacterium infantis thymidine kinase/nucleoside analogue ganciclovir (BI-TK/GCV) treatment system which was proven to exhibit sustainable anti-tumor growth activity and induce apoptosis in bladder cancer, a proteomic approach of isobaric tags for relative and absolute quantification (iTRAQ), followed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) was used. 192 down-regulated and 210 up-regulated proteins were identified after treatment with BI-TK/GCV system in Sprague-Dawley (SD) rats. Western blot analysis and immunohistochemistry analysis confirmed that Peroxiredoxin-I (Prx-I) was significantly down-regulated in bladder cancer after treatment. Prx-I silencing by transfection of Prx-I shRNA significantly suppressed growth, promoted apoptosis and regulated the cell cycle in T24 cells and reduced the phospho-NF-κB p50 and p65 protein expression which revealed the links between Prx-I and NF-κB pathway implied by Ingenuity pathway analysis (IPA). These findings yield new insights into the therapy of bladder cancer, revealing Prx-I as a new therapeutic target and indicating BI-TK/GCV system as a prospective therapy by down-regulation of Prx-I through NF-κB signaling pathway. Show MeSH Major Bifidobacterium/enzymology/genetics/physiology Ganciclovir/pharmacology/therapeutic use Peroxiredoxins/deficiency/genetics/metabolism* Proteomics* Thymidine Kinase/genetics* Urinary Bladder Neoplasms/drug therapy/genetics/metabolism/pathology Minor* Animals Apoptosis/drug effects/genetics Cell Cycle/drug effects/genetics Cell Proliferation/drug effects/genetics Down-Regulation/drug effects/genetics Female Gene Knockdown Techniques Genetic Therapy NF-kappa B/metabolism Rats Rats, Sprague-Dawley Signal Transduction/drug effects/genetics Transcriptome/drug effects/genetics Related in: MedlinePlus	© Copyright Policy Related In: Results - Collection License Show All Figures getmorefigures.php?uid=PMC4048271&req=5 pone-0098764-g005: Prx-I knockdown inhibited the proliferation of T24 cells in vitro.The growth rates in Prx-I knockdown group was significantly reduced, compared with the parental and con sh groups, measured by CCK8 assay. Mentions: The effects of Prx-I shRNA transfection on T24 cell growth were investigated through CCK8 assays. A slight inhibition in growth was observed at 24 h after transfection. Furthermore, obvious inhibitory effects on cell proliferation were observed in Prx-I knockdown-cells at 48 and 72 h, compared with the parental and con sh groups (Figure 5, p<0.05), suggesting that the inhibition of Prx-I could suppress T24 cell growth in vitro.

Proteomic analysis of bladder cancer indicates Prx-I as a key molecule in BI-TK/GCV treatment system.

Jiang L, Xiao X, Ren J, Tang Y, Weng H, Yang Q, Wu M, Tang W - PLoS ONE (2014)

Bottom Line: In order to understand the molecular mechanisms of Bifidobacterium infantis thymidine kinase/nucleoside analogue ganciclovir (BI-TK/GCV) treatment system which was proven to exhibit sustainable anti-tumor growth activity and induce apoptosis in bladder cancer, a proteomic approach of isobaric tags for relative and absolute quantification (iTRAQ), followed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) was used. 192 down-regulated and 210 up-regulated proteins were identified after treatment with BI-TK/GCV system in Sprague-Dawley (SD) rats.Western blot analysis and immunohistochemistry analysis confirmed that Peroxiredoxin-I (Prx-I) was significantly down-regulated in bladder cancer after treatment.Prx-I silencing by transfection of Prx-I shRNA significantly suppressed growth, promoted apoptosis and regulated the cell cycle in T24 cells and reduced the phospho-NF-κB p50 and p65 protein expression which revealed the links between Prx-I and NF-κB pathway implied by Ingenuity pathway analysis (IPA).

View Article: PubMed Central - PubMed

Affiliation: Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.

ABSTRACT

In order to understand the molecular mechanisms of Bifidobacterium infantis thymidine kinase/nucleoside analogue ganciclovir (BI-TK/GCV) treatment system which was proven to exhibit sustainable anti-tumor growth activity and induce apoptosis in bladder cancer, a proteomic approach of isobaric tags for relative and absolute quantification (iTRAQ), followed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) was used. 192 down-regulated and 210 up-regulated proteins were identified after treatment with BI-TK/GCV system in Sprague-Dawley (SD) rats. Western blot analysis and immunohistochemistry analysis confirmed that Peroxiredoxin-I (Prx-I) was significantly down-regulated in bladder cancer after treatment. Prx-I silencing by transfection of Prx-I shRNA significantly suppressed growth, promoted apoptosis and regulated the cell cycle in T24 cells and reduced the phospho-NF-κB p50 and p65 protein expression which revealed the links between Prx-I and NF-κB pathway implied by Ingenuity pathway analysis (IPA). These findings yield new insights into the therapy of bladder cancer, revealing Prx-I as a new therapeutic target and indicating BI-TK/GCV system as a prospective therapy by down-regulation of Prx-I through NF-κB signaling pathway.

Show MeSH

Related in: MedlinePlus

Prx-I knockdown inhibited the proliferation of T24 cells in vitro.The growth rates in Prx-I knockdown group was significantly reduced, compared with the parental and con sh groups, measured by CCK8 assay.

Related In: Results - Collection

License

Show All Figures

getmorefigures.php?uid=PMC4048271&req=5

pone-0098764-g005: Prx-I knockdown inhibited the proliferation of T24 cells in vitro.The growth rates in Prx-I knockdown group was significantly reduced, compared with the parental and con sh groups, measured by CCK8 assay.

Mentions: The effects of Prx-I shRNA transfection on T24 cell growth were investigated through CCK8 assays. A slight inhibition in growth was observed at 24 h after transfection. Furthermore, obvious inhibitory effects on cell proliferation were observed in Prx-I knockdown-cells at 48 and 72 h, compared with the parental and con sh groups (Figure 5, p<0.05), suggesting that the inhibition of Prx-I could suppress T24 cell growth in vitro.